Search

Your search keyword '"Kastelein, John J.P."' showing total 24 results
Start Over Author "Kastelein, John J.P." Publisher massachusetts medical society
24 results on '"Kastelein, John J.P."'

1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Author

Nissen, Steven E., primary, Lincoff, A. Michael, additional, Brennan, Danielle, additional, Ray, Kausik K., additional, Mason, Denise, additional, Kastelein, John J.P., additional, Thompson, Paul D., additional, Libby, Peter, additional, Cho, Leslie, additional, Plutzky, Jorge, additional, Bays, Harold E., additional, Moriarty, Patrick M., additional, Menon, Venu, additional, Grobbee, Diederick E., additional, Louie, Michael J., additional, Chen, Chien-Feng, additional, Li, Na, additional, Bloedon, LeAnne, additional, Robinson, Paula, additional, Horner, Maggie, additional, Sasiela, William J., additional, McCluskey, Jackie, additional, Davey, Deborah, additional, Fajardo-Campos, Pedro, additional, Petrovic, Predrag, additional, Fedacko, Jan, additional, Zmuda, Witold, additional, Lukyanov, Yury, additional, and Nicholls, Stephen J., additional

Published
2023
Full Text
View/download PDF

2. Statin therapy with ezetimibe or niacin in high-risk patients

Author

Kastelein, John J.P. and Bots, Michiel L.

Subjects
Atherosclerosis -- Drug therapy, Atherosclerosis -- Risk factors, Cholesterol, LDL -- Health aspects, Niacin -- Usage, Niacin -- Health aspects, Drug therapy, Combination
Abstract

The authors comment on the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies (ARBITER 6-HALTS) study on the use of ez etimibe or extended-release niacin together with statin in patients at high risk of atherosclerosis. They assert the study's findings support the concept that using statins to reduce LDL cholesterol together with niacin to raise HDL cholesterol levels is more effective in patients with high cardiovascular risk.

Published
2009

3. A randomized trial of rosuvastatin in the prevention of venous thromboembolism

Author

Glynn, Robert J., Danielson, Eleanor, Francisco, M.I.A, Fonseca, A.H., Genest, Jacques, Gotto, Antonio M., Jr., Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFadyen, Jean G., Nordestgaard, Borge C., Shepherd, James, Willerson, James T., and Ridker, Paul M.

Subjects
Thromboembolism -- Drug therapy, Thromboembolism -- Prevention, Rosuvastatin -- Usage, Rosuvastatin -- Health aspects
Abstract

The effects of the stain therapy and use of rosuvastatin on the prevention of venous thromboembolism are analyzed. The results indicate that venous thromboembolism can be easily prevented in healthy persons by an effective use of rosuvastatin.

Published
2009

4. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Author

Ridker, Paul M., Danielson, Eleanor, Fonseca, Francisco A.H., Genest, Jacques, Gotto, Antonio M. Jr, Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFayden, Jean G., Nordestgaard, Borge G., Shepherd, James, Willerson, James T., and Glynn, Robert J.

Subjects
C-reactive protein -- Health aspects, Cardiovascular diseases -- Prevention, Cardiovascular diseases -- Drug therapy, Rosuvastatin -- Usage
Abstract

A study was conducted to evaluate the efficacy of Rosuvastatin as a means of preventing cardiovascular events in men and women with elevated C-reactive protein. Results indicated that rosuvastatin significantly reduced the incidence of cardiovascular events in men and women.

Published
2008

5. Simvastatin with or without Ezetimibe in familial Hypercholesterolemia

Author

Kastelein, John J.P., Stroes, Erik S.G., Akdim, Fatima, Zwinderman, Aeilko H., Bots, Michiel L., Stalenhoef, Anton F.H., Visseren, Frank L.J., Sijbrands, Eric J.G., Trip, Mieke D, Stein, Evan A., Gaudet, Daniel, Duivenvoorden, Raphael, Veltri, Enrico P., Marais, A. David, and de Groot, Eric

Subjects
Atherosclerosis -- Care and treatment, Hypercholesterolemia -- Health aspects, Hypercholesterolemia -- Research, Blood lipoproteins -- Health aspects, Lipoproteins -- Health aspects, Proteolipids -- Health aspects
Abstract

A study to explain the efficacy of ezetimibe, which reduces LDL cholesterol on the progression of atherosclerosis, is conducted. Results indicate that a combination of simvastatin and ezetimibe does not show any significant changes in hypercholesterolemia but simvastatin alone did work better.

Published
2008

6. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

Author

Santos, Raul D., Ruzza, Andrea, Hovingh, G. Kees, Wiegman, Albert, Mach, François, Kurtz, Christopher E., Hamer, Andrew, Bridges, Ian, Bartuli, Andrea, Bergeron, Jean, Szamosi, Tamás, Santra, Saikat, Stefanutti, Claudia, Descamps, Olivier S., Greber-Platzer, Susanne, Luirink, Ilse, Kastelein, John J.P., Gaudet, Daniel, HAUSER-RCT INVESTIGATORS, Stéphenne, Xavier, Sokal, Etienne, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Experimental Vascular Medicine, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Paediatric Metabolic Diseases, General Paediatrics, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, APH - Methodology, APH - Quality of Care, ACS - Heart failure & arrhythmias, ACS - Diabetes & metabolism, and ACS - Pulmonary hypertension & thrombosis

Subjects
Male, medicine.medical_specialty, Heterozygote, animal structures, Adolescent, medicine.drug_class, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Monoclonal antibody, Antibodies, LDL, Hyperlipoproteinemia Type II, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Double-Blind Method, Drug Therapy, Internal medicine, Monoclonal, medicine, Humans, 030212 general & internal medicine, Child, Humanized, biology, Cholesterol, business.industry, Anticholesteremic Agents, fungi, Antibodies, Monoclonal, Humanized, Cholesterol, LDL, Drug Therapy, Combination, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Proprotein Convertase 9, Treatment Outcome, General Medicine, Proprotein convertase, medicine.disease, Evolocumab, Endocrinology, chemistry, Combination, biology.protein, lipids (amino acids, peptides, and proteins), Antibody, business, Lipoprotein
Abstract

Background: Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known. Methods: We conducted a 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia. Patients 10 to 17 years of age who had received stable lipid-lowering treatment for at least 4 weeks before screening and who had an LDL cholesterol level of 130 mg per deciliter (3.4 mmol per liter) or more and a triglyceride level of 400 mg per deciliter (4.5 mmol per liter) or less were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab (420 mg) or placebo. The primary end point was the percent change in LDL cholesterol level from baseline to week 24; key secondary end points were the mean percent change in LDL cholesterol level from baseline to weeks 22 and 24 and the absolute change in LDL cholesterol level from baseline to week 24. Results: A total of 157 patients underwent randomization and received evolocumab (104 patients) or placebo (53 patients). At week 24, the mean percent change from baseline in LDL cholesterol level was -44.5% in the evolocumab group and -6.2% in the placebo group, for a difference of -38.3 percentage points (P

Published
2020

7. Effects of torcetrapid in patients at high risk for coronary events

Author

Barter, Philip J., Caulfield, Mark, Eriksson, Mats, Grundy, Scott M., Kastelein, John J.P., Komajda, Michel, Lopez-Sendon, Jose, Mosca, Lori, Tardif, Jean-Claude, Waters, David D., Shear, Charles L., Revkin, James H., Buhr, Kevin A., Risher, Marian R., Tall, Alan R., and Brewer, Bryan

Subjects
Torcetrapib (Medication) -- Research, Torcetrapib (Medication) -- Complications and side effects, Anticholesteremic agents -- Research, Anticholesteremic agents -- Complications and side effects, Heart -- Abnormalities, Heart -- Risk factors
Abstract

A randomized, double-blind trial was conducted to determine efficacy of torcetrapib, a potent cholesteryl ester transfer protein inhibitor to reduce major cardiovascular events. The trial was terminated prematurely as it increased risk of death and cardiac events in patients receiving torcetrapib.

Published
2007

8. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

Author

Kastelein, John J.P., van Leuven, Sander I, Burgess, Leslie, Evans, Greg W., Kuivenhoven, Jan A., Barter, Philip J., Revkin, James H., Grobbee, Diederick E., Riley, Ward A., Shear, Charles L., Duggan, William T., and Bots, Michiel L.

Subjects
Hypercholesterolemia -- Drug therapy, Atherosclerosis -- Drug therapy, High density lipoproteins -- Research, Anticholesteremic agents -- Dosage and administration
Abstract

A trial is conducted to test if torcetrapib, an inhibitor of cholesteryl ester transfer protein can minimize atherosclerotic vascular disease by raising the levels of high-density lipoprotein (HDL) cholesterol in 850 patients with heterozygous familial hypercholesterolemia. It is concluded that use of torcetrapib with atorvastatin, did not reduce the progress of atherosclerosis, inspite of substantial, rise in the level of HDL cholesterol and reduction the LDL cholesterol and triglycerides level.

Published
2007

9. Intensive lipid lowering with atorvastatin in patients with stable coronary disease

Author

LaRosa, John C., Fruchart, Jean-Charles, Wenger, Nanette K., Gotto, Antonio M., Grundy, Scott M., Waters, David D., Greten, Heiner, Shear, Charles, Kastelein, John J.P., Barter, Philip, and Shepherd, James

Subjects
Coronary heart disease -- Care and treatment, Cholesterol, LDL -- Measurement
Abstract

Lowering low-density lipoprotein (LDL) cholesterol levels below recommended levels is beneficial in patients with acute coronary syndromes. Intensive lipid-lowering therapy with 80mg of atorvastatin per day in patients with stable coronary heart disease (CHD) provides significant clinical benefit beyond that afforded by treatment with 10mg of atorvastatin per day.

Published
2005

10. Evinacumab for Homozygous Familial Hypercholesterolemia

Author

Raal, Frederick J., primary, Rosenson, Robert S., additional, Reeskamp, Laurens F., additional, Hovingh, G. Kees, additional, Kastelein, John J.P., additional, Rubba, Paolo, additional, Ali, Shazia, additional, Banerjee, Poulabi, additional, Chan, Kuo-Chen, additional, Gipe, Daniel A., additional, Khilla, Nagwa, additional, Pordy, Robert, additional, Weinreich, David M., additional, Yancopoulos, George D., additional, Zhang, Yi, additional, and Gaudet, Daniel, additional

Published
2020
Full Text
View/download PDF

11. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Author

Ray, Kausik K., primary, Wright, R. Scott, additional, Kallend, David, additional, Koenig, Wolfgang, additional, Leiter, Lawrence A., additional, Raal, Frederick J., additional, Bisch, Jenna A., additional, Richardson, Tara, additional, Jaros, Mark, additional, Wijngaard, Peter L.J., additional, and Kastelein, John J.P., additional

Published
2020
Full Text
View/download PDF

12. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Author

Raal, Frederick J., primary, Kallend, David, additional, Ray, Kausik K., additional, Turner, Traci, additional, Koenig, Wolfgang, additional, Wright, R. Scott, additional, Wijngaard, Peter L.J., additional, Curcio, Danielle, additional, Jaros, Mark J., additional, Leiter, Lawrence A., additional, and Kastelein, John J.P., additional

Published
2020
Full Text
View/download PDF

13. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis

Author

Kuivenhoven, Jan Albert, Jukema, J. Wouter, Zwinderman, Aeilko H., Knijff, Peter de, McPherson, Ruth, Bruschke, Albert V.G., Lie, Kong I., and Kastelein, John J.P.

Subjects
Genetic polymorphisms -- Health aspects, Transferases -- Genetic aspects, Pravastatin -- Health aspects, Atherosclerosis -- Development and progression
Abstract

Variants in the cholesteryl ester transfer protein (CETP) gene may alter the effectiveness of a cholesterol-lowering drug in men with coronary artery disease. CETP has a role in the metabolism of high-density lipoprotein (HDL) cholesterol. Researchers analyzed the DNA of 807 men with coronary artery disease, then randomly assigned them to receive cholesterol-lowering pravastatin or placebo. The drug failed to slow progression of the disease in 16% of the men, all of whom had a particular variant of the gene. Tests for this gene may help predict a patient's response to pravastatin.

Published
1998

15. Mendelian Randomization Study of ACLY and Cardiovascular Disease

Author

Ference, Brian A., primary, Ray, Kausik K., additional, Catapano, Alberico L., additional, Ference, Thatcher B., additional, Burgess, Stephen, additional, Neff, David R., additional, Oliver-Williams, Clare, additional, Wood, Angela M., additional, Butterworth, Adam S., additional, Di Angelantonio, Emanuele, additional, Danesh, John, additional, Kastelein, John J.P., additional, and Nicholls, Stephen J., additional

Published
2019
Full Text
View/download PDF

17. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Author

Ridker, Paul M, primary, Everett, Brendan M., additional, Thuren, Tom, additional, MacFadyen, Jean G., additional, Chang, William H., additional, Ballantyne, Christie, additional, Fonseca, Francisco, additional, Nicolau, Jose, additional, Koenig, Wolfgang, additional, Anker, Stefan D., additional, Kastelein, John J.P., additional, Cornel, Jan H., additional, Pais, Prem, additional, Pella, Daniel, additional, Genest, Jacques, additional, Cifkova, Renata, additional, Lorenzatti, Alberto, additional, Forster, Tamas, additional, Kobalava, Zhanna, additional, Vida-Simiti, Luminita, additional, Flather, Marcus, additional, Shimokawa, Hiroaki, additional, Ogawa, Hisao, additional, Dellborg, Mikael, additional, Rossi, Paulo R.F., additional, Troquay, Roland P.T., additional, Libby, Peter, additional, and Glynn, Robert J., additional

Published
2017
Full Text
View/download PDF

18. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

Author

Ridker, Paul M, primary, Tardif, Jean-Claude, additional, Amarenco, Pierre, additional, Duggan, William, additional, Glynn, Robert J., additional, Jukema, J. Wouter, additional, Kastelein, John J.P., additional, Kim, Albert M., additional, Koenig, Wolfgang, additional, Nissen, Steven, additional, Revkin, James, additional, Rose, Lynda M., additional, Santos, Raul D., additional, Schwartz, Pamela F., additional, Shear, Charles L., additional, and Yunis, Carla, additional

Published
2017
Full Text
View/download PDF

19. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Author

Ridker, Paul M, primary, Revkin, James, additional, Amarenco, Pierre, additional, Brunell, Robert, additional, Curto, Madelyn, additional, Civeira, Fernando, additional, Flather, Marcus, additional, Glynn, Robert J., additional, Gregoire, Jean, additional, Jukema, J. Wouter, additional, Karpov, Yuri, additional, Kastelein, John J.P., additional, Koenig, Wolfgang, additional, Lorenzatti, Alberto, additional, Manga, Pravin, additional, Masiukiewicz, Urszula, additional, Miller, Michael, additional, Mosterd, Arend, additional, Murin, Jan, additional, Nicolau, Jose C., additional, Nissen, Steven, additional, Ponikowski, Piotr, additional, Santos, Raul D., additional, Schwartz, Pamela F., additional, Soran, Handrean, additional, White, Harvey, additional, Wright, R. Scott, additional, Vrablik, Michal, additional, Yunis, Carla, additional, Shear, Charles L., additional, and Tardif, Jean-Claude, additional

Published
2017
Full Text
View/download PDF

20. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Author

Ray, Kausik K., primary, Landmesser, Ulf, additional, Leiter, Lawrence A., additional, Kallend, David, additional, Dufour, Robert, additional, Karakas, Mahir, additional, Hall, Tim, additional, Troquay, Roland P.T., additional, Turner, Traci, additional, Visseren, Frank L.J., additional, Wijngaard, Peter, additional, Wright, R. Scott, additional, and Kastelein, John J.P., additional

Published
2017
Full Text
View/download PDF

21. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

Author

Gaudet, Daniel, primary, Alexander, Veronica J., additional, Baker, Brenda F., additional, Brisson, Diane, additional, Tremblay, Karine, additional, Singleton, Walter, additional, Geary, Richard S., additional, Hughes, Steven G., additional, Viney, Nicholas J., additional, Graham, Mark J., additional, Crooke, Rosanne M., additional, Witztum, Joseph L., additional, Brunzell, John D., additional, and Kastelein, John J.P., additional

Published
2015
Full Text
View/download PDF

22. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Author

Robinson, Jennifer G., primary, Farnier, Michel, additional, Krempf, Michel, additional, Bergeron, Jean, additional, Luc, Gérald, additional, Averna, Maurizio, additional, Stroes, Erik S., additional, Langslet, Gisle, additional, Raal, Frederick J., additional, El Shahawy, Mahfouz, additional, Koren, Michael J., additional, Lepor, Norman E., additional, Lorenzato, Christelle, additional, Pordy, Robert, additional, Chaudhari, Umesh, additional, and Kastelein, John J.P., additional

Published
2015
Full Text
View/download PDF

23. Genetic Variant of the Scavenger Receptor BI in Humans

Author

Vergeer, Menno, primary, Korporaal, Suzanne J.A., additional, Franssen, Remco, additional, Meurs, Illiana, additional, Out, Ruud, additional, Hovingh, G. Kees, additional, Hoekstra, Menno, additional, Sierts, Jeroen A., additional, Dallinga-Thie, Geesje M., additional, Motazacker, Mohammad Mahdi, additional, Holleboom, Adriaan G., additional, Van Berkel, Theo J.C., additional, Kastelein, John J.P., additional, Van Eck, Miranda, additional, and Kuivenhoven, Jan Albert, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results